Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.96M Sell
5,580
-1,505
-21% -$537K 0.11% 75
2025
Q4
$2.32M Sell
7,085
-32
-0.4% -$10.2K 0.12% 75
2025
Q3
$2.01M Buy
7,117
+32
+0.5% +$9.28K 0.12% 74
2025
Q2
$1.98M Buy
7,085
+846
+14% +$240K 0.12% 74
2025
Q1
$1.94M Hold
6,239
0.14% 65
2024
Q4
$1.63M Sell
6,239
-53
-0.8% -$15.7K 0.11% 71
2024
Q3
$2.03M Sell
6,292
-56
-0.9% -$18.3K 0.15% 54
2024
Q2
$1.98M Sell
6,348
-723
-10% -$212K 0.16% 51
2024
Q1
$2.01M Buy
7,071
+825
+13% +$241K 0.16% 61
2023
Q4
$1.8M Sell
6,246
-588
-9% -$160K 0.18% 51
2023
Q3
$1.84M Buy
+6,834
New +$1.71M 0.21% 47
2022
Q3
Sell
-2,235
Closed -$544K 179
2022
Q2
$544K Hold
2,235
0.06% 121
2022
Q1
$540K Buy
2,235
+95
+4% +$21.8K 0.05% 131
2021
Q4
$481K Buy
2,140
+405
+23% +$85.5K 0.06% 123
2021
Q3
$369K Sell
1,735
-53
-3% -$12.2K 0.03% 155
2021
Q2
$436K Buy
1,788
+18
+1% +$4.43K 0.03% 128
2021
Q1
$440K Buy
1,770
+3
+0.2% +$716 0.04% 132
2020
Q4
$406K Buy
1,767
+32
+2% +$7.38K 0.03% 124
2020
Q3
$441K Buy
+1,735
New +$430K 0.04% 120

Other funds holding AMGN

BBR Partners's AMGN Position: Q1 2026 in Review

BBR Partners reduced its Amgen (AMGN) stake by 21% in Q1 2026, selling an estimated $537K and leaving 5,580 shares worth $1.96M. The position accounts for 0.11% of the portfolio, ranked #75.

BBR Partners first reported a position in AMGN in Q3 2020 and has held it in 19 quarters since. The position peaked at $2.32M in Q4 2025. 3,127 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • BBR Partners held 5,580 shares of Amgen worth $1.96M as of Q1 2026.
  • BBR Partners sold 1,505 Amgen shares in Q1 2026, an estimated $537K.
  • Amgen made up 0.11% of BBR Partners's portfolio in Q1 2026, its #75 holding.
  • BBR Partners first reported a position in Amgen in Q3 2020 and has held it in 19 quarters since.
  • BBR Partners's Amgen position peaked at $2.32M in Q4 2025.
  • 3,127 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on BBR Partners's 13F filing for Q1 2026, filed 12 May 2026.